Covid-19 roundup: CanSino eyes more overseas PhIII sites as Canada trial reportedly stalls; Indian drugmaker surges on 30-person data
Having leveraged connections in Canada for a planned Phase III trial of its Covid-19 vaccine, CanSino is venturing out to a few more others as it plots a global late-stage program.
“We are contacting Russia, Brazil, Chile and Saudi Arabia, and it’s still in discussion,” Dongxu Qiu, executive director and co-founder of CanSino, said at a conference in Suzhou, China, per Reuters.
The trial is likely to start “pretty soon,” he added, with plans to recruit 40,000 participants total.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.